A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

Author： Tolcher Anthony   Appleman Leonard   Shapiro Geoffrey   Mita Alain   Cihon Frank   Mazzu Arthur   Sundaresan Pavur  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.67, Iss.4, 2011-04, pp. : 751-764

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer

By Yamada Yasuhide   Kiyota Naomi   Fuse Nozomu   Kato Ken   Minami Hironobu   Hashizume Kensei   Kuroki Yoshihiro   Ito Yuichiro   Ohtsu Atsushi  

Gastric Cancer, Vol. 17, Iss. 1, 2014-01 ,pp. : 161-172

Springer Publishing Company

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

By Becerra Carlos   Salazar Ramon   Garcia-Carbonero Rocio   Thomas Anne   Vázquez-Mazón Federico   Cassidy James   Maughan Tim   Castillo Manuel   Iveson Tim   Yin Donghua   Green Stephanie   Bergsland Emily  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 695-702

Springer Publishing Company

Access to resources Recommend Favorite

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

By Bamias A.   Dafni U.   Karadimou A.   Timotheadou E.   Aravantinos G.   Psyrri A.   Xanthakis I.   Tsiatas M.   Koutoulidis V.   Constantinidis C.   Hatzimouratidis C.   Samantas E.   Visvikis A.   Chrisophos M.   Stravodimos K.   Deliveliotis C.   Eleftheraki A.   Pectasides D.   Fountzilas G.   Dimopoulos M. A.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1011-1017

Oxford University Press

Access to resources Recommend Favorite